A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function (clinicaltrials.gov) - Oct 1, 2026 - P1 | N=30 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting
Enrollment open • Chronic Kidney Disease • Nephrology • Renal Disease
|